

WALDER WYSS ADVISED VERSANT VENTURES IN MATTERHORN BIOSCIENCES LAUNCHING

Posted on 12 August 2020



Category: [Deal & transactions](#)

Tags: [Alexander Gutmans](#), [Ex-Featured](#), [Jessica Aeschbach Flórez](#), [Karina Tschon](#), [Markus R. Frick](#), [Robert von Rosen](#), [Walder Wyss](#)



Matterhorn Biosciences, a Swiss biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins, has received a financing of USD 30 million from **Versant Ventures**. It is the most recent company to be launched out of Versant's Ridgeline Discovery Engine based in Basel, Switzerland.

The advisor

Walder Wyss [advised Versant Ventures in connection with this transaction](#). The team was led by partner **Alexander Gutmans (Transaction/M&A & Venture Capital - pictured) and partner **Robert von Rosen (Transaction/M&A & Venture Capital)** and included partner **Markus R. Frick (IP/IT)**, senior associate **Jessica Aeschbach Flórez (Transaction/M&A)** and associate **Karina Tschon (Transaction/M&A)**.**